IFN-ω Activators
IFN-ω Activators are primarily composed of agonists for Toll-like receptors (TLRs) and stimulator of interferon genes (STING). TLR agonists such as Poly I:C, Imiquimod, Resiquimod, Gardiquimod, Loxoribine, and Bropirimine can activate TLR3, TLR7 or TLR9. This activation leads to the initiation of the TRIF-dependent or MyD88-dependent signaling pathways, which can result in the activation of transcription factors such as IRF3, IRF7, and NF-κB. These transcription factors can enhance the expression ofIFN-ω, leading to its increased functional activity.
On the other hand, STING agonists such as Poly (dA:dT), 2'3'-cGAMP, DMXAA, c-di-GMP, and c-di-AMP can activate the STING-TBK1 pathway. This activation leads to the stimulation of the transcription factor IRF3, which can enhance the expression of IFN-ω. Therefore, these chemicals can directly enhance the functional activity of IFN-ω through specific signaling pathways or biological processes that IFN-ω is involved in. These specific pathways include the TRIF-dependent signaling pathway, the MyD88-dependent signaling pathway, and the STING-TBK1 pathway. Activation of these pathways results in the activation of transcription factors that directly enhance the expression and functional activity of IFN-ω. The mechanisms of these activators provide vital insights into the complex pathways and regulatory mechanisms that govern the functional activity of IFN-ω.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Poly I:C is a synthetic analog of double-stranded RNA. It can activate Toll-like receptor 3 (TLR3), which leads to activation of the TRIF-dependent signaling pathway, ultimately resulting in the activation of IRF3 and NF-κB. These transcription factors can upregulate the expression of IFN-ω and increase its functional activity. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod is a small molecule that acts as an agonist of Toll-like receptor 7 (TLR7). Activation of TLR7 leads to the MyD88 dependent signaling pathway, resulting in the activation of NF-κB and IRF7. These transcription factors can enhance the expression of IFN-ω. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Resiquimod is another agonist of TLR7. Its activation of TLR7 leads to the MyD88 dependent signaling pathway, resulting in the activation of NF-κB and IRF7. These transcription factors can enhance the expression of IFN-ω. | ||||||
2′,3′-cGAMP | 1441190-66-4 | sc-507484 | 10 mg | $1800.00 | ||
2'3'-cGAMP is a cyclic dinucleotide that acts as an agonist for STING. Its activation of STING triggers the TBK1-IRF3 signaling pathway, which can enhance the expression of IFN-ω. | ||||||
DMXAA | 117570-53-3 | sc-207592 sc-207592A | 5 mg 25 mg | $129.00 $590.00 | 1 | |
DMXAA is a small molecule STING agonist. Activation of STING by DMXAA triggers the TBK1-IRF3 signaling pathway, which can enhance the expression of IFN-ω. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod is a TLR7 agonist. Its activation of TLR7 leads to the MyD88 dependent signaling pathway, resulting in the activation of NF-κB and IRF7. These transcription factors can enhance the expression of IFN-ω. | ||||||
Loxoribine | 121288-39-9 | sc-203118 sc-203118A | 25 mg 100 mg | $124.00 $390.00 | 1 | |
Loxoribine is a guanosine analog that acts as an agonist of TLR7. Activation of TLR7 by loxoribine leads to the MyD88-dependent signaling pathway, resulting in the activation of NF-κB and IRF7. These transcription factors can enhance the expression of IFN-ω. | ||||||
Bropirimine | 56741-95-8 | sc-362719 sc-362719A | 10 mg 50 mg | $52.00 $183.00 | ||
Bropirimine is a synthetic immunomodulator that acts as an agonist of TLR7. Activation of TLR7 by bropirimine leads to the MyD88 dependent signaling pathway, resulting in the activation of NF-κB and IRF7. These transcription factors can enhance the expression of IFN-ω. | ||||||